Orchiectomy

Spay and Neuter Market Expected to Reach $2.24 Billion in 2023 with 5.8% CAGR: A Growing Trend in Pet Ownership Drives Demand

Retrieved on: 
Thursday, October 12, 2023
Ethos, Benchmark, HPM, Anicura, COVID-19, Hospital, Agriculture, Customer insight, Cat, Uterus, Global Insight, Country, Animal, Tubing (recreation), Pet, VCA Animal Hospitals, Growth, Virbac, Dog, Reproduction, Hysterectomy, Orchiectomy, Pet industry, Veterinary medicine, Cryptocurrency, Retail, Video game, Birth control

DUBLIN, Oct. 12, 2023 /PRNewswire/ -- The "Spay And Neuter Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 12, 2023 /PRNewswire/ -- The "Spay And Neuter Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • This growth is poised to continue, with the spay and neuter market anticipated to reach $2.6 billion in 2027, sustaining a CAGR of 4.7%.
  • The spay and neuter market research report offers comprehensive statistics, including global market size, regional shares, and competitor insights.
  • The growing trend of pet adoption is expected to drive spay and neuter market growth.

AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360

Retrieved on: 
Tuesday, October 3, 2023
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, Janssen Pharmaceuticals, Disease, Journal of Oncology Pharmacy Practice, PharMerica, HRR, ADP, Abiraterone acetate, CI, National Cancer Institute, Janssen, ADT, Toxicity, Pharmacy, Prednisone, Death, BRCA2, Hospital, Specialty pharmacy, HIV disease progression rates, Patient, Risk, Testosterone, SEER, Johnson & Johnson, Gonadotropin-releasing hormone, BRCA, FDA, PARP, Orchiectomy, Phase, CYP17, Prostate cancer, Pharmaceutical industry, Epidemiology

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson for AKEEGA™ (niraparib and abiraterone acetate).

Key Points: 
  • Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by The Janssen Pharmaceutical Companies of Johnson & Johnson for AKEEGA™ (niraparib and abiraterone acetate).
  • Patients should be selected for therapy based on an FDA-approved test for AKEEGA.
  • Patients taking AKEEGA should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
  • “Onco360 is thankful for the opportunity to partner with the team at Janssen and become a specialty pharmacy provider for AKEEGA,” said Benito Fernandez, Chief Commercial Officer.

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

Retrieved on: 
Tuesday, October 4, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Hypertension, Cancer, U.S. Securities and Exchange Commission, HRR, Review, Clinical trial, Man, COVID-19, Warfarin, Enzyme, Hypercalcaemia, DNA, CYP2C19, Global Oncology, Orchiectomy, Research, PSA, Arm, PFE, Global health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Plasma, Patient, Prostate cancer, TSE, BRCA, Adult, INR, Food, CYP3A4, FDA, Breast, RPF, Testosterone, Hyponatremia, Hypermagnesemia, Risk, CYP2C8, ADT, Hyperglycemia, PARP, Melanoma, Documentation, Blood, 2, Inc., Death, Medicine, DNA repair, Metastasis, ADP, CRPC, Safety, NYSE, Breast cancer, Medivation, HER2, CYP2C9, Medical imaging, Pharmaceutical industry, Generic drug, Astellas Pharma, MCRPC, Pfizer

At the time of topline analysis, the safety of TALZENNA plus XTANDI were generally consistent with the known safety profile of each medicine.

Key Points: 
  • At the time of topline analysis, the safety of TALZENNA plus XTANDI were generally consistent with the known safety profile of each medicine.
  • Detailed results from TALAPRO-2 will be submitted for presentation at a near-term medical congress.
  • In addition to the TALAPRO-2 trial, the combination of TALZENNA plus XTANDI is being investigated in the TALAPRO-3 trial ( NCT04821622 ), a global, randomized, double-blind, placebo-controlled Phase 3 study in men with HRR-deficient mCSPC.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)

Retrieved on: 
Thursday, July 28, 2022
Pulmonary embolism, Liver, Edema, Neoplasm, BPH, Hypercalcaemia, Capsule, Testosterone, Birth, LHRH, Woman, Gynecomastia, Radiation, Sleep apnea, Gonadotropin, Trauma, Cardiovascular disease, Androgen, DVT, Luteinizing hormone, Prostate cancer, Orchiectomy, FSH, Cryptorchidism, Primary, Risk, Adult, Deep vein thrombosis, Hypogonadism, T4, Chronic lung disease, Safety, Cancer, Orchitis, VTE, Thyroid, Hypergonadotropic hypogonadism, Suicidal ideation, Heart, Klinefelter syndrome, CIII, Patient, PE, Thyroxine-binding globulin, Serum, Breast cancer, Man, Blood pressure, Depression, Spermatogenesis, Obesity, Methyltestosterone, BP, MACE, Birth control, Dietary supplement, Pharmaceutical industry, Medical imaging

NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for additional claims that cover its oral testosterone replacement product, JATENZO (testosterone undecanoate).

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patients baseline cardiovascular risk and ensure blood pressure is adequately controlled.
  • Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

Retrieved on: 
Monday, May 9, 2022
T4, LHRH, Birth, Androgen, Methyltestosterone, CIII, Hypergonadotropic hypogonadism, Orchitis, Hypogonadism, Blood pressure, Woman, Thyroid, Neoplasm, Spermatogenesis, Liver, MACE, Breast cancer, Deep vein thrombosis, DVT, Cardiovascular disease, Radiation, Chronic lung disease, Suicidal ideation, Patient, Trauma, Pulmonary embolism, Gynecomastia, Testosterone, Sleep apnea, Edema, Heart, Luteinizing hormone, Risk, Gonadotropin, Cancer, VTE, Obesity, Primary, Klinefelter syndrome, Orchiectomy, FSH, Adult, Thyroxine-binding globulin, PE, Cryptorchidism, Prostate cancer, Hypercalcaemia, Serum, BP, BPH, Depression, Capsule, Man, Safety, Birth control, Dietary supplement, Pharmaceutical industry, Medical imaging

NORTHBROOK, Ill., May 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for JATENZO (testosterone undecanoate) will be presented in the form of an abstract at the 2022 American Urological Association Annual Meeting taking place at the New Orleans Ernest N. Morial Convention Center in New Orleans May 13-16, 2022.

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patients baseline cardiovascular risk and ensure blood pressure is adequately controlled.
  • Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

Phase III Investigational Trial of NUBEQA® (darolutamide) in Combination with Docetaxel and Androgen Deprivation Therapy (ADT) Meets Primary Endpoint of Significantly Increasing Overall Survival (OS) in Patients with mHSPC

Retrieved on: 
Friday, December 3, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Man, Prostate cancer, Senior, MFS, Docetaxel, Gonadotropin-releasing hormone, Death, Diagnosis, Recurrence, Malignancy, Trust, Hematuria, Risk, CYP3A4, Heart, CRPC, Birth, Orchiectomy, DASL, Cancer, OATP1B1, Pregnancy, Research, ADT, Documentation, Trial of the century, Urinary retention, SSE, Clinician, Congress, American Cancer Society, Female, Safety, Phase, Orion Corporation, Tablet, FDA, Growth, Patient, Cardiac arrest, Ageing, BCRP, AR, Pulmonary embolism, Developmental toxicity, Plasma, Group, OATP1B3, ARAMIS, Oncology, RPF, Pneumonia, Ari, Mortality, Science, AUC, Disease, Birth control, Pharmaceutical industry, Medical imaging, Vaccine, the ARASENS Trial1, the ARANOTE Trial, NUBEQA® (darolutamide), Metastatic Hormone-Sensitive Prostate Cancer, Oncology at Bayer, Bayer, THE ARASENS TRIAL1, THE ARANOTE TRIAL, NUBEQA® (DAROLUTAMIDE), METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, ONCOLOGY AT BAYER, BAYER

In the ARASENS trial, NUBEQA in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to docetaxel and ADT.

Key Points: 
  • In the ARASENS trial, NUBEQA in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to docetaxel and ADT.
  • The ARANOTE trial (NCT04736199) is a randomized, double-blind, placebo-controlled Phase III study of NUBEQA in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).
  • In the clinical study, 1,509 patients were randomized in a 2:1 ratio to receive 600 mg of NUBEQA orally twice daily or androgen deprivation therapy (ADT) alone.
  • NUBEQA (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA

Retrieved on: 
Thursday, October 14, 2021
Risk, Androgen, Suicidal ideation, DVT, Luteinizing hormone, Primary, Liver, Gynecomastia, Heart, T4, Trauma, Thyroid, MACE, FSH, Man, Hypogonadism, Radiation, Breast cancer, Cancer, Testosterone, Thyroxine-binding globulin, Klinefelter syndrome, Adult, Serum, Safety, Cardiovascular disease, Birth, Capsule, Woman, Gonadotropin, LHRH, PE, BP, VTE, Pulmonary embolism, Patient, Spermatogenesis, Sleep apnea, Orchitis, Edema, Methyltestosterone, BPH, Hypergonadotropic hypogonadism, Blood pressure, Chronic lung disease, Neoplasm, Prostate cancer, Deep vein thrombosis, Hypercalcaemia, Cryptorchidism, Orchiectomy, Depression, Obesity, CIII, Birth control, Dietary supplement, Pharmaceutical industry, Medical imaging

NORTHBROOK, Ill., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new real-world experience data for JATENZO® (testosterone undecanoate) will be presented at the 22nd Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA), taking place at The Westin Kierland in Scottsdale, Arizona, October 21-24, 2021.

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patients baseline cardiovascular risk and ensure blood pressure is adequately controlled.
  • Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.